Agustin Aviles1, Natividad Neri, M Jesus Nambo. 1. Hematology Department, Oncology Hospital National Medical Center, IMSS Mexico, Mexico. agustin.aviles@imss.gob.mx
Abstract
OBJECTIVES: To analyze the role of genotype in patients with diffuse large B-cell lymphoma primary of breast (DLBCL-PB) treated with chemotherapy or immunochemotherapy. METHODS: We carried out a retrospective analysis in 104 patients with DLBCL-PB who were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or immunochemotherapy: R-CHOP (adding rituximab) and also carried out an analysis of genotype, studied with immunohistochemistry, as a prognostic factor. RESULTS: Seventy-seven percent of patients showed the non-GCB (germinal center B) genotype. Patients treated with CHOP had a complete response of 70%; actuarial curves at 5 years showed that disease-free survival was 66 % and overall survival was 52% and that it was not statistically different than patients treated with R-CHOP: 78%, 61%, and 53%, respectively. When genotype was analyzed to assess the impact in prognosis, no statistical differences were observed. Patients treated with R-CHOP and non-GCB genotype have a complete response of 77%, disease-free survival of 56%, and overall survival of 66% that were not statistically different than patients with GCB: 80%, 60%, and 60% respectively, (P: 0.81, 0.5, and 0.66, respectively). CONCLUSIONS: We confirm that the non-GCB genotype is most frequent in DLBCL-PB, but the addition of rituximab did not improve outcome in primary breast lymphoma with non-GCB phenotype.
OBJECTIVES: To analyze the role of genotype in patients with diffuse large B-cell lymphoma primary of breast (DLBCL-PB) treated with chemotherapy or immunochemotherapy. METHODS: We carried out a retrospective analysis in 104 patients with DLBCL-PB who were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or immunochemotherapy: R-CHOP (adding rituximab) and also carried out an analysis of genotype, studied with immunohistochemistry, as a prognostic factor. RESULTS: Seventy-seven percent of patients showed the non-GCB (germinal center B) genotype. Patients treated with CHOP had a complete response of 70%; actuarial curves at 5 years showed that disease-free survival was 66 % and overall survival was 52% and that it was not statistically different than patients treated with R-CHOP: 78%, 61%, and 53%, respectively. When genotype was analyzed to assess the impact in prognosis, no statistical differences were observed. Patients treated with R-CHOP and non-GCB genotype have a complete response of 77%, disease-free survival of 56%, and overall survival of 66% that were not statistically different than patients with GCB: 80%, 60%, and 60% respectively, (P: 0.81, 0.5, and 0.66, respectively). CONCLUSIONS: We confirm that the non-GCB genotype is most frequent in DLBCL-PB, but the addition of rituximab did not improve outcome in primary breast lymphoma with non-GCB phenotype.
Authors: Peter J Hosein; Jocelyn C Maragulia; Matthew P Salzberg; Oliver W Press; Thomas M Habermann; Julie M Vose; Martin Bast; Ranjana H Advani; Robert Tibshirani; Andrew M Evens; Nahida Islam; John P Leonard; Peter Martin; Andrew D Zelenetz; Izidore S Lossos Journal: Br J Haematol Date: 2014-01-27 Impact factor: 6.998
Authors: Fernando Franco; Julia González-Rincón; Javier Lavernia; Juan F García; Paloma Martín; Carmen Bellas; Miguel A Piris; Lucia Pedrosa; José Miramón; José Gómez-Codina; Delvys Rodríguez-Abreu; Isidro Machado; Carmen Illueca; Jesús Alfaro; Mariano Provencio; Margarita Sánchez-Beato Journal: Oncotarget Date: 2017-10-24